Please login to the form below

Not currently logged in
Email:
Password:

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen will consolidate the biotech’s manufacturing strategy

Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.

Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.

Roozen’s career history has also seen him serve in numerous positions for Pharmacell, which was recently acquired by Lonza.

Miguel Forte, chief executive officer of Zelluna, said: “Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing.

“His experience, acquired on both side’s of the Atlantic will provide invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers.

“He will play a big part in the execution of Zelluna’s manufacturing strategy for clinical trials and commercialisation.”

20th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics